References
- World Health Organization. Model list of essential medicines14th ed. WHO, Geneva, http://mednet3.who.int/EMLib/
- European Medicines Evaluation Agency: http://www.emea.eu.int/pdfs/human/press/pr/13270607en. pdf
- Hanley J A, McNeil B J. Method for comparing the area under two ROC curves derived from the same cases. Radiology 1983; 148: 839–843
- Peyron R, Aubeny E, Targosz V, et al. Early pregnancy interruption with RU 486 (mifepristone) and the orally active prostaglandin misoprostol. N Engl J Med 1993; 328: 1509–1513
- Aubeny E, Peyron R, Turpin C L, et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int J Fertil Menopausal Stud 1995; 40(Suppl. 2)85–91
- Winikoff B, Sivin I, Coyaji K J, et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: A comparative trial of mifepristone-misoprostol vs.surgical abortion. Am J Obstet Gynecol 1997; 176: 431–437
- Spitz I M, Bardin C W, Benton L, Robbins A. Early termination of pregnancy with mifepristone (RU486) and the orally active prostaglandin misoprostol. New Engl J Med 1998; 21: 1509–1513
- Aubeny E, Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur J Contracept Reprod Health Care 2000; 5: 171–176
- Aubeny E. A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins. Eur J Contracept Reprod Health Care 2001; 6: 54–55
- Wiebe L, Dunn S, Guilbert E, et al. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet Gynecol 2002; 99: 813–819
- Faucher P, Baunot N, Madelenat P. The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients. Gynecol Obstet Fertil 2005; 33: 220–227
- Bartley J, Tong S, Everington D, Baird D T. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception 2000; 62: 297–303
- Tang O S, Thong K-J, Baird D T. Second trimester medical abortion with mifepristone and gemeprost: A review of 956 cases. Contraception 2001; 64: 29–32
- Child T J, Thomas J, Rees M, MacKenzie I Z. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Human Reprod 2001; 16: 67–71
- Coyaji K, Krishna U, Ambardekar S, et al. Are two doses of misoprostol after mifepristone for early abortion better than one. BJOG 2007; 114: 271–278
- Cowett A A, Cohen L S, Lichtenberg E S, Stika C S. Ultrasound evaluation of the endometrium after medical termination of pregnancy. Obstet Gynecol 2004; 103: 871–875
- Harwood B, Meckstroth K R, Mishell D R, Jr, Jain J K. Serum beta-human chorionic gonadotrophin levels and endometrial thickness after medical abortion. Contraception 2001; 63: 255–256
- Haimov-Kochman R, Arbel R, Sciaky Tamir Y, et al. Risk factors for unsuccessful medical abortion with mifepristone and misoprostol. Acta Obstet Gynecol Scand 2007; 86: 462–466
- Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion: Ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109: 190–195